Experimental Models and their Predictive Value in New Drug Development: A Critical Appraisal: I. Toxicity Models.

  • Abraham Goldin
  • Philip S. Schein
Part of the Developments in Oncology book series (DION, volume 23)

Abstract

The toxicity of antitumor agents for the host constitutes a prime limiting factor in clinical chemotherapy and it is essential that models be employed which will predict for both the quantitative and qualitative toxicity of new drugs undergoing development (1–4). The potential risks for the patient are significant: a) in order to maximize therapeutic efficacy and with the goal of cure, doses of drug in a moderately toxic range are generally employed; b) the testing of new compounds in the clinic is frequently accomplished with patients who have received prior therapy or are in an advanced stage of disease, so that the ability to withstand drug toxicity is diminished; c) the patients are usually treated for an extended period of time with repeated regimens. Further, many of the antitumor agents act via cytotoxicity for the host, increasing the risk of mutagenesis, carcinogenesis and teratogenesis.

Keywords

Toxicity Pancreatitis Anemia Doxorubicin Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schein, PS: Preclinical toxicology of antitumor agents: Cancer Res (37): 1934–1937, 1977.PubMedGoogle Scholar
  2. 2.
    Schein PS, Winokur SH: Immunosuppressive and cytotoxic chemotherapy: Long-term complications. Ann Intern Med (82) 84–95, 1975.PubMedGoogle Scholar
  3. 3.
    Schein PS, Davis RD, Carter SK, Newman J, Schein DR, Rail DP: The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin Pharmacol Therap (11) No 1, 3–40, 1970.Google Scholar
  4. 4.
    Goldin, A, Rozencweig M, Guarino AM, Schein P: Quantitative and qualitative prediction of toxicity from animals to human. In Tagnon HJ, Staquet, MJ. Controversies in cancer. Design of trials and treatment. Masson Pub USA Inc, 83–104, 1979.Google Scholar
  5. 5.
    Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM: Procedures for preclinical toxicologic evaluation of cancer chemothera- peutic agents. Protocols of the Laboratory of Toxicology. Cancer Chemother Rep (4) No 1, 1–30, 1973.Google Scholar
  6. 6.
    Pinkel D: The use of body surface as a criterion of drug dosage in cancer chemotherapy. Cancer Res (18): 853–856, 1956.Google Scholar
  7. 7.
    Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep (50): 219–244, 1966.PubMedGoogle Scholar
  8. 8.
    Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (25): 1354–1364, 1975.Google Scholar
  9. 9.
    Rozencweig M, Von Hoff DD, Staquet MJ, Schein PS, Penta JS, Goldin A, Muggia FM, Freireich EJ, DeVita VT Jr: Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials (4): 21–28, 1981.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Abraham Goldin
  • Philip S. Schein

There are no affiliations available

Personalised recommendations